High-administered activity in-111 octreotide therapy with concomitant radiosensitizing 5fu chemotherapy for treatment of neuroendocrine tumors: Preliminary experience

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 5, 2009, Pages 527-533

  Kong, Grace ^a   Johnston, Val ^a   Ramdave, Shakher ^a   Lau, Eddie ^a   Rischin, Danny ^a   Hicks, Rodney J ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Cancer; Chemotherapy; Imaging; Molecular imaging; PET; Radionuclide; Radionuclide therapy; Targeted therapy; Thyroid cancer

Indexed keywords

FLUOROURACIL; LUTETIUM 177; PENTETREOTIDE; PENTETREOTIDE IN 111;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PAIN; CANCER REGRESSION; CARCINOID; CATHETER THROMBOSIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCAGONOMA; HORMONE RESPONSE; HUMAN; INSULINOMA; LYMPHADENITIS; LYMPHOCYTOPENIA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; PANCREAS ISLET CELL TUMOR; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RADIOSENSITIZATION; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDIUM RADIOISOTOPES; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; RADIATION-SENSITIZING AGENTS; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 70449092370     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2009.0644     Document Type: Article

References (24)

1. Oberg K. Neuroendocrine gastrointestinal tumors-a condensed overview of diagnosis and treatment. Ann Oncol 1999;10:S3.
2. Krenning EP, et al. Somatostatin receptor: Scintigraphy and radionuclide therapy. Digestion 1996;57 (Suppl 1) 57.
3. Kwekkeboom DJ, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124.
4. Van Essen M, et al. Peptide receptor radionuclide therapywith radiolabelled somatostatin analogues in patients with somatostatin receptor-positive tumours. Acta Oncol 2007;46:723.
5. Krenning EP, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol 1999;10 (Suppl 2):S23.
6. Buscombe JR, Caplin ME, Hilson AJ. Long-term efficacy of high-activity 111In-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med 2003;44:1.
7. Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. NEJM, 1985;312:1465.
8. Kvols LK. Radiation sensitizers: A selective review of molecules targeting DNA and non-DNA targets. J Nucl Med 2005;46 (Suppl 1):187S.
9. Krook JE, et al. Effective surgical adjuvant therapy for highrisk rectal carcinoma. NEJMed 1991;324:709.
10. Millward MJ, et al. Carboplatin dosing based on measurement of renal function-experience at the Peter MacCallum Cancer Institute. Aust N Z J Med 1996;26:372.
11. Ahlman H, Nilsson O, Olausson M. Interventional treatment of the carcinoid syndrome. Neuroendocrinology 2004;80 (Suppl 1):67.
12. Ruszniewski P, and O'Toole D. Ablative therapies for liver metastases of gastroenteropancreatic endocrine tumors. Neuroendocrinology 2004;80 (Suppl 1):74.
13. O'Toole D, et al. Chemotherapy for gastroenteropancreatic endocrine tumours. Neuroendocrinology 2004;80 (Suppl 1):79.
14. Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. NEJM 1980;303:1189.
15. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 2001;12 (Suppl 2):S111.
16. Rougier P, Mitry E. Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion 2000;62 (Suppl 1):73.
17. Anthony LB, et al. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002;32:123.
18. Tiensuu Janson E, et al. Treatment with high-dose [(111)In- DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors-evaluation of therapeutic and toxic effects. Acta Oncol 1999;38:373.
19. Valkema R, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: The Rotterdam experience. Semin Nucl Med 2002;32:110.
20. Kwekkeboom, D.J., et al., Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754.
21. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med, 2000. 41(10): p. 1704-1713
22. de Jong M, Krenning E. New advances in peptide receptor radionuclide therapy. J Nucl Med 2002;43:617.
23. Nguyen C, et al. Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy. J Nucl Med 2004;45:1660.
24. van Essen M, et al. Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2008;35:743.